文献速递肾癌与肾肿瘤

透明细胞乳头状肾细胞癌的临床病理与分子特征及其诊疗意义

The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management.
PubMed 文献 · Eur Urol · 2020-10-10

该研究纳入89例透明细胞乳头状肾细胞癌(CCPRCC)患者,并与1120例局限性透明细胞肾细胞癌(ccRCC)及129例1型乳头状肾细胞癌(pRCC)患者进行对比。结果显示CCPRCC具有独特的流行病学和分子特征(体细胞变异少、线粒体DNA耗竭),且多灶性CCPRCC组织学一致性仅44%(7/16),纯CCPRCC多灶患者5年无转移,而混合组织学患者预后更差(CSS,log rank p=0.034)。

要点

  • CCPRCC多见于女性和非裔美国人,且更易表现为同侧多发病灶或双侧病变。
  • 分子特征为体细胞变异较少和线粒体DNA耗竭,有别于常见肾癌亚型。
  • 多灶性CCPRCC组织学一致性低(44%),单灶活检可能遗漏侵袭性病变。

核心结论

  • CCPRCC具有独特的分子和流行病学特征,可用于改进诊断方法。
  • CCPRCC总体呈惰性,但多灶性肿瘤诊断困难,单一肿块活检可能遗漏共存侵袭性疾病。
  • 多灶性CCPRCC组织学不一致率高,对管理有重要临床意义。

研究设计与样本

  • 研究纳入89例CCPRCC患者,并与1120例局限性ccRCC和129例1型pRCC患者进行临床病理特征比较。
  • 采用非参数统计检验比较组间特征,用Kaplan-Meier法计算总生存、癌症特异性生存(CSS)和无转移生存。
  • 对部分CCPRCC肿瘤进行基因组分析,并与其他RCC亚型比较。

主要发现

  • CCPRCC队列中女性占45%(ccRCC和pRCC中为32%),非裔美国人占19%(其他组为3%)。
  • 分子分析显示CCPRCC体细胞变异较少,线粒体DNA耗竭程度更高。
  • 多灶性CCPRCC中不同肾细胞癌肿块的组织学一致性为44%(7/16);仅患CCPRCC的患者5年后无转移;混合组织学患者CSS更差(log rank p=0.034)。

临床怎么用

  • 诊断CCPRCC时应评估多灶性和双侧病变的可能性。
  • 对于多灶性肾肿瘤,单灶活检可能遗漏侵袭性组织学类型,需谨慎解读。
  • 多灶性CCPRCC患者应关注组织学不一致性,可能需更全面评估以指导管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clear cell papillary renal cell carcinoma (CCPRCC) is a recently described tumor entity. Several questions remain about its epidemiology, molecular features, and clinical behavior. OBJECTIVE: To comprehensively evaluate clinicopathologic and molecular features of CCPRCC, and compare it with more common kidney cancer subtypes. DESIGN, SETTING, AND PARTICIPANTS: We identified 89 CCPRCC patients and compared their clinicopathologic features with 1120 localized clear cell renal cell carcinoma (ccRCC) and 129 type 1 papillary renal cell carcinoma (pRCC) patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Nonparametric statistical testing was used to compare relevant features between tumor types. Overall, cancer-specific survival (CSS) and metastasis-free survival estimates were calculated from initial diagnosis using the Kaplan-Meier method. Patients with ipsilateral multifocal disease were explored further. A subset of CCPRCC tumors underwent genomic analysis and were compared with other RCC subtypes. RESULTS AND LIMITATIONS: A higher proportion of female (45% vs 32%) and African-American (19% vs 3%) patients were observed in the CCPRCC cohort than in the ccRCC and pRCC cohorts. CCPRCC tumors also had increased odds of presenting with additional ipsilateral masses (odds ratio [OR]: 4.41 [confidence interval {CI}: 2.34, 8.15], p < 0.001) and bilateral disease (OR: 4.80 [CI: 2.40, 9.59], p < 0.001) compared with ccRCC tumors. On molecular analysis, CCPRCC tumors showed fewer somatic aberrations and a greater degree of mitochondrial DNA depletion. In multifocal CCPRCC tumors, histologic concordance among the different renal cell carcinoma masses was estimated at 44% (7/16), and none of the individuals presenting exclusively with CCPRCC tumors developed metastatic disease after 5 yr. In contrast, multifocal tumors with CCPRCC and other nonconcordant histologies were more likely to experience adverse outcomes (CSS, log rank p = 0.034). CONCLUSIONS: CCPRCC is characterized by distinct molecular and epidemiologic features that could be used to refine current diagnostic approaches. Although their clinical course is generally indolent, multifocal CCPRCC tumors represent a unique diagnostic challenge. In this context, single-mass biopsies could miss concomitant aggressive disease, with a potential negative impact on patient outcomes. Furthermore, high discordance rates in multifocal CCPRCC tumors have important clinical implications in management. PATIENT SUMMARY: We explored the molecular and clinical features of clear cell papillary renal cell carcinoma (CCPRCC) relative to other kidney cancer subtypes. While CCPRCC generally conveys a good prognosis, additional caution should be taken when it is diagnosed using biopsy if multiple kidney masses are present.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Weng S, DiNatale RG, Silagy A, et al. The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. Eur Urol. 2020. PMID: 33046271. doi:10.1016/j.eururo.2020.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。